Related Experiment Videos
Adverse drug events and medication errors in Australia
William B Runciman1, Elizabeth E Roughead, Susan J Semple
1Department of Anaesthesia and Intensive Care, Level 4, Eleanor Harrald Building, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000, Australia. wrunciman@bigpond.com
Summary
Adverse drug events (ADEs) are common in Australia, affecting 2-4% of hospital admissions and often preventable. Anticoagulant, anti-inflammatory, and cardiovascular drugs are frequently implicated, highlighting the need for improved monitoring and prevention strategies.
Area of Science:
- Health Services Research
- Pharmacovigilance
- Medication Safety
Background:
- Adverse drug events (ADEs) and medication errors pose significant challenges within healthcare systems.
- Understanding the prevalence and impact of ADEs is crucial for improving patient safety.
- Australia faces a substantial burden from medication-related harm.
Purpose of the Study:
- To comprehensively review existing information on adverse drug events (ADEs) and medication errors in Australia.
- To identify common drug classes associated with ADEs and medication errors.
- To assess the preventability and impact of these events on patient outcomes.
Main Methods:
- Systematic literature reviews were conducted.
- Data from Australian Bureau of Statistics, Institute of Health and Welfare, Council for Health Care Standards, and Patient Safety Foundation were analyzed.
- Medical record reviews and routine data collections were utilized.
Main Results:
- 2-4% of hospital admissions are medication-related, with up to 30% in elderly patients (>75 years); three-quarters are potentially preventable.
- Routine data capture less than half of ADEs compared to medical record reviews.
- Anticoagulants, anti-inflammatory, and cardiovascular drugs are frequently implicated in ADEs, representing over half of all events.
Conclusions:
- Adverse drug events are prevalent in the Australian healthcare system.
- Preventable ADEs, particularly those involving anticoagulants, anti-inflammatory, and cardiovascular drugs, represent a significant public health issue.
- Enhanced methods for monitoring and preventing ADEs are essential for improving patient safety and reducing healthcare costs.